Vigna S R, Thorndyke M C, Williams J A
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4355-9. doi: 10.1073/pnas.83.12.4355.
An evolutionary basis for the distinct forms of cholecystokinin (CCK) receptors in the mammalian brain and pancreas was examined. The brains and pancreases of ratfish, frog, snake, and chicken contained saturable, high-affinity binding sites for iodinated porcine CCK-33. In the ectothermic species, the brain and pancreas CCK receptors exhibited nearly the same relative specificities for various CCKs and gastrins. Sulfated CCK-8 and sulfated gastrin-17 were the most potent while their nonsulfated analogs and gastrin-4 were less potent. By contrast, in the chicken, the specificities of brain and pancreas CCK receptors closely resembled their mammalian counterparts. We conclude that brain and pancreas CCK receptors with new specificities for binding CCKs and gastrins evolved at the level of the divergence of endotherms (birds and mammals) from reptiles. We propose that the prior evolution of gastrin provided the selection pressure for these changes. The endotherm pancreas receptor arose in evolution by narrowing its requirement for the position of a sulfated tyrosine residue in its ligands from either the sixth or seventh position from the carboxyl terminus to the seventh position only. The endotherm brain receptor arose in evolution by losing its requirement for a sulfated ligand and by transferring its high-affinity binding domain from the tyrosine residue in the carboxyl termini of CCK and gastrin to the carboxyl-terminal tetrapeptide active site common to CCKs and gastrins.
研究了哺乳动物脑和胰腺中胆囊收缩素(CCK)受体不同形式的进化基础。银鲛、青蛙、蛇和鸡的脑和胰腺中含有对碘化猪CCK - 33的可饱和、高亲和力结合位点。在变温动物中,脑和胰腺CCK受体对各种CCK和胃泌素表现出几乎相同的相对特异性。硫酸化CCK - 8和硫酸化胃泌素 - 17活性最强,而它们的非硫酸化类似物和胃泌素 - 4活性较弱。相比之下,在鸡中,脑和胰腺CCK受体的特异性与它们的哺乳动物对应物非常相似。我们得出结论,对CCK和胃泌素具有新结合特异性的脑和胰腺CCK受体是在恒温动物(鸟类和哺乳动物)与爬行动物分化的水平上进化而来的。我们提出,胃泌素的先前进化为这些变化提供了选择压力。恒温动物胰腺受体在进化过程中出现,是通过将其配体中硫酸化酪氨酸残基位置的要求从羧基末端的第六或第七位缩小到仅第七位。恒温动物脑受体在进化过程中出现,是通过失去对硫酸化配体的要求,并将其高亲和力结合域从CCK和胃泌素羧基末端的酪氨酸残基转移到CCK和胃泌素共有的羧基末端四肽活性位点。